Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
OpenAI Rejects Apple Trade Secret Theft Claims 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
OpenAI Nears Astra AI Model Launch With Safety Focus 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Add as a preferred source on Google
WEST LAFAYETTE, March 05, 2018 -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , today announced that the company’s management team will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12th at 2:50 p.m. EDT.
A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering Phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR-T therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
